Serum Institute of India has actually gotten Indian regulative approval to resume regional scientific trials of AstraZeneca’s prospective COVID19 vaccine, a source familiar with the matter said on Wednesday.
- Last Updated: September 16, 2020, 12: 15 PM IST
- FOLLOW US ON:
MUMBAI/BENGALURU: Serum Institute of India has gotten Indian regulatory approval to resume local clinical trials of AstraZeneca’s prospective COVID-19 vaccine, a source familiar with the matter said on Wednesday.
The approval came from the Drugs Controller General of India, the source said.
AstraZeneca has actually resumed British medical trials of the vaccine– one of the most advanced in advancement for COVID-19– after they were stopped briefly earlier this month following a serious side impact in a trial participant.
Trials have also resumed in Brazil and South Africa.
The trial stays on hold in the United States, the U.S. Food and Drug Administration’s top official validated on Tuesday.